TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000SU5F128

Market Closed - Deutsche Boerse AG 20:42:57 17/05/2024 BST
5.78 EUR +0.35% Intraday chart for TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL
Current month-6.77%
1 month-19.27%
Date Price Change
17/05/24 5.78 +0.35%
16/05/24 5.76 -4.79%
15/05/24 6.05 +0.67%
14/05/24 6.01 -1.48%
13/05/24 6.1 -0.97%

Delayed Quote Deutsche Boerse AG

Last update May 17, 2024 at 08:42 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying BIOMARIN PHARMACEUTICAL INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SU5F12
ISINDE000SU5F128
Date issued 08/12/2023
Strike 15.66 $
Maturity Unlimited
Parity 10 : 1
Emission price 7.5
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 7.81
Lowest since issue 5.63

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
77.56 USD
Average target price
109.3 USD
Spread / Average Target
+40.95%
Consensus